Rosiglitazone Extended Release 2mg
AVA102670
Phase 3 small_molecule completed
Quick answer
Rosiglitazone Extended Release 2mg for Alzheimer's Disease is a Phase 3 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline
- Indication
- Alzheimer's Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed